Jack A. Khattar Sells 55,578 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Key Points

• CEO Jack Khattar of Supernus Pharmaceuticals sold 55,578 shares at an average price of $46.01, resulting in a total transaction of approximately $2.56 million, and a ownership decrease of 4.77%.
• The stock experienced a minor decline, trading at $45.82 with a market capitalization of $2.57 billion and a 12-month high of $46.79.
• Analyst ratings for Supernus Pharmaceuticals vary, with a mix of "Buy," "Hold," and "Overweight" ratings, while the average price target stands at $43.00.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) CEO Jack A. Khattar sold 55,578 shares of the business's stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $46.01, for a total transaction of $2,557,143.78. Following the completion of the transaction, the chief executive officer directly owned 1,110,231 shares of the company's stock, valued at approximately $51,081,728.31. This represents a 4.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Supernus Pharmaceuticals Trading Down 2.6%

Shares of SUPN traded down $1.20 during mid-day trading on Friday, hitting $45.46. 415,075 shares of the company traded hands, compared to its average volume of 624,694. The stock has a market capitalization of $2.55 billion, a price-to-earnings ratio of 39.53 and a beta of 0.79. The business has a 50-day moving average of $39.42 and a 200 day moving average of $34.58. Supernus Pharmaceuticals, Inc. has a one year low of $29.16 and a one year high of $46.78.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of SUPN. Rubric Capital Management LP bought a new position in Supernus Pharmaceuticals in the second quarter valued at approximately $21,908,000. Armistice Capital LLC boosted its stake in Supernus Pharmaceuticals by 7.4% in the first quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company's stock valued at $170,169,000 after acquiring an additional 360,000 shares during the last quarter. Sofinnova Investments Inc. boosted its stake in Supernus Pharmaceuticals by 53.5% in the second quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company's stock valued at $25,192,000 after acquiring an additional 278,575 shares during the last quarter. Woodline Partners LP boosted its stake in Supernus Pharmaceuticals by 124.8% in the fourth quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company's stock valued at $15,326,000 after acquiring an additional 235,257 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Supernus Pharmaceuticals by 248.0% in the fourth quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company's stock valued at $10,581,000 after acquiring an additional 208,552 shares during the last quarter.

Analyst Ratings Changes

SUPN has been the subject of several research reports. Piper Sandler lifted their target price on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a research note on Friday, August 29th. Zacks Research upgraded Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Finally, Cantor Fitzgerald raised their target price on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Supernus Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $43.00.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.